KRAS and neoplasm: Genomic analysis revealed neither an ALK gene rearrangement nor EGFR, BRAF or HER2 gene mutations, but an activating point mutation of the KRAS gene (p.G12C, exon 2) and therefore this tumor could be considered a non-responder case to EGFR-TKI therapy.